TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 0.880nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.09nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.26nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.34nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.44nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.56nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.58nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.59nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.93nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.99nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.20nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.91nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.95nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.17nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.63nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.71nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 4nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: <5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 6nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 6.90nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 6.90nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair